EMA and FDA set common principles for AI in medicine development

EMA and the U.S. Food and Drug Administration (FDA) have jointly identified ten principles to inform, enhance and promote the use of artificial intelligence (AI) for generating evidence across all phases of the drug life cycle, from early research and clinical trials to manufacturing and safety monitoring.